Abstract: Adapting crosslinking with triglycidyl amine (TGA) to incorporate the use of a particular type of anti-calcification agent provides a broad-reaching solution to the problem in vivo bioprosthesis calcification. The anti-calcification agent in question includes a polyphosphonate compound that contains a functional group, which serves as a reaction site between the polyphosphonate and a polyepoxide. The functional group is reactive enough to dominate the reaction between the polyphosphonate and the polyepoxide, thereby excluding the chelating oxygen atoms of polyphosphonate from the reaction, protecting their anti-calcification ability. Furthermore, the high reactivity of the functional group allows the polyphosphonate to attach to the polyepoxide more completely, which improves the calcification resistance of bioprosthetic material with which the polyepoxide is crosslinked.

Abstract: Reactive dyes of formula ##STR1## wherein Y is a radical of formula ##STR2## or--CO--A--SO.sub.2 --X (3)Z is --NH.sub.2, an unsubstituted or a substituted aliphatic or aromatic amino group; A is an unsubstituted or a substituted aliphatic or aromatic bridging group, and X is .beta.-sulfatoethyl, .beta.-thiosulfatoethyl, .beta.-phosphatoethyl, .beta.-acyloxyethyl, .beta.-haloethyl or vinyl; the benzene rings I, II and III may contain further substituents in addition to 2 to 4 sulfo groups and, in the benzene ring II, to the radical --NH--Y; and the reactive dyes of formula (1) contain only a single fiber-reactive radical, are especially suitable for dyeing or printing cellulosic fiber materials by the methods customarily employed for reactive dyes, and give dyeings and prints of good fastness properties in high color yield.

Abstract: New 3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines and their pharmaceutically acceptable acid addition salts, and methods for their synthesis are described. These compounds are useful as antiarrhythmic agents in the treatment of heart disorders. The new compounds are made by reacting a 3-carbalkoxyamino-5-halogenacyl-5H-dibenz[b,f]azepines with an amine to form the desired target product, which can be optionally converted into its pharmaceutically acceptable acid addition salt.